2024
Lipid-Lowering Therapy Use When Indicated and Subsequent Ischemic Stroke Severity.
Gordon-Kundu B, Peyravi R, Garg A, Baker A, Salas S, Levien M, Faridi K, de Havenon A, Krumholz H, Sheth K, Forman R, Sharma R. Lipid-Lowering Therapy Use When Indicated and Subsequent Ischemic Stroke Severity. Journal Of The American Heart Association 2024, 14: e033365. PMID: 39699007, DOI: 10.1161/jaha.123.033365.Peer-Reviewed Original ResearchConceptsPrescribed lipid-lowering therapyNational Institutes of Health Stroke Scale scoreAcute ischemic strokeLipid-lowering therapyStroke Scale scoreStroke severityGuidelines-Stroke registryAtherosclerotic cardiovascular disease eventsCardiovascular disease eventsScale scoreGuideline-recommended criteriaSevere stroke symptomsStudy assessed usePropensity score subclassificationLipid-lowering therapy useNational InstituteLogistic regression modelsCholesterol management guidelinesPoststroke disabilityElevated low-density lipoprotein cholesterolInstitutional GetSmall vessel diseaseTime of acute ischemic strokeLarge-artery atherosclerosisLow-density lipoprotein cholesterol
2023
Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy
Mottola G, Welty F, Mojibian H, Faridi K. Case report: Coronary atherosclerosis in a patient with long-standing very low LDL-C without lipid-lowering therapy. Frontiers In Cardiovascular Medicine 2023, 10: 1272944. PMID: 37795488, PMCID: PMC10546007, DOI: 10.3389/fcvm.2023.1272944.Peer-Reviewed Case Reports and Technical NotesLipid-lowering therapyLDL-C levelsCoronary atherosclerosisLow LDL-C levelsLow-density lipoprotein cholesterolCardiovascular risk factorsLeft coronary systemRight coronary arteryLow serum levelsDevelopment of atherosclerosisNonobstructive coronary atherosclerosisRoutine laboratory dataTomography angiography scansApoB-containing lipoproteinsHeterozygous familial hypobetalipoproteinemiaAnomalous originMyxoma resectionAcute strokeAtrial myxomaCardiovascular riskLipoprotein cholesterolPlaque regressionDiabetes mellitusPrimordial preventionSerum levelsMoving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
Faridi K, Desai N. Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2023, 14: 100491. PMID: 36969953, PMCID: PMC10036885, DOI: 10.1016/j.ajpc.2023.100491.Commentaries, Editorials and Letters
2022
Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)
Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyAtherosclerotic cardiovascular diseaseTreatment of hyperlipidemiaProportion of patientsElectronic health recordsPragmatic trialHigh riskCardiovascular diseaseProprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitorsHigh-risk atherosclerotic cardiovascular diseaseSubtilisin/kexin type 9 inhibitorsLow-density lipoprotein cholesterol reductionImportant public health implicationsEnrollment of patientsPublic health implicationsUsual careSecondary outcomesPrimary outcomeGuideline recommendationsCholesterol reductionPatientsLDLHyperlipidemiaScalable interventionsOutpatients
2017
Serum vitamin D and change in lipid levels over 5Â y: The Atherosclerosis Risk in Communities study
Faridi KF, Zhao D, Martin SS, Lupton JR, Jones SR, Guallar E, Ballantyne CM, Lutsey PL, Michos ED. Serum vitamin D and change in lipid levels over 5 y: The Atherosclerosis Risk in Communities study. Nutrition 2017, 38: 85-93. PMID: 28526388, PMCID: PMC5443111, DOI: 10.1016/j.nut.2017.01.008.Peer-Reviewed Original ResearchConceptsIncident dyslipidemiaLipid changesLongitudinal community-based studyAdjusted average differencesDemographic-adjusted modelsLipid-lowering therapySerum vitamin DCommunity-based studyBaseline dyslipidemiaLipid trendsIncident useCardiovascular riskClinical characteristicsSD ageVitamin DARIC studyAtherosclerosis RiskCardiovascular diseaseLipid levelsDyslipidemiaCommunity studyRatio of TCHDLMixed effects modelsBaseline
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply